Celcuity LLC (NASDAQ:CELC) — Market Cap & Net Worth
Market Cap & Net Worth: Celcuity LLC (CELC)
Celcuity LLC (NASDAQ:CELC) has a market capitalization of $3.83 Billion ($3.83 Billion) as of September 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4231 globally and #1469 in its home market, demonstrating a -13.58% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Celcuity LLC's stock price $82.70 by its total outstanding shares 46271259 (46.27 Million). Also see Celcuity LLC asset portfolio for a full breakdown of the balance sheet.
Celcuity LLC Market Cap History: 2017 to 2026
Celcuity LLC's market capitalization history from 2017 to 2026. Data shows growth from $876.84 Million to $3.83 Billion (21.56% CAGR). Also see Celcuity LLC (CELC) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Celcuity LLC is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.14% | #108 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.01% | #490 of 3165 |
Weight: Celcuity LLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Celcuity LLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Celcuity LLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check CELC stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CELC by Market Capitalization
Companies near Celcuity LLC in the global market cap rankings as of September 16, 2026. Review Celcuity LLC tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Celcuity LLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Celcuity LLC Historical Marketcap From 2017 to 2026
Between 2017 and today, Celcuity LLC's market cap moved from $876.84 Million to $ 3.83 Billion, with a yearly change of 21.56%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.83 Billion | -17.08% |
| 2025 | $4.62 Billion | +661.96% |
| 2024 | $605.69 Million | -10.16% |
| 2023 | $674.17 Million | +4.00% |
| 2022 | $648.26 Million | +6.22% |
| 2021 | $610.32 Million | +44.00% |
| 2020 | $423.84 Million | -13.91% |
| 2019 | $492.33 Million | -55.65% |
| 2018 | $1.11 Billion | +26.60% |
| 2017 | $876.84 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Celcuity LLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.83 Billion USD |
| MoneyControl | $3.83 Billion USD |
| MarketWatch | $3.83 Billion USD |
| marketcap.company | $3.83 Billion USD |
| Reuters | $3.83 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Celcuity LLC
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2… Read more